Full-Time

General Ledger Accountant

Updated on 7/23/2026

Replimune Group

Replimune Group

201-500 employees

Develops oncolytic viral immunotherapies for cancer

Compensation Overview

$80.5k - $104k/yr

+ Bonus + Equity Grants

Burlington, MA, USA

Hybrid

Hybrid role; on-site at least 2 days per week in Woburn, Massachusetts.

Category
Accounting (1)
Required Skills
Excel/Numbers/Sheets

Get referred to Replimune Group

Find people who can refer or advise you

Requirements
  • A bachelor’s degree in Accounting or Finance
  • Proficiency in MS Office, particularly Excel
  • A high degree of accuracy and attention to detail
  • Strong analytical and problem-solving skills
Responsibilities
  • Prepare and record journal entries for Replimune, Inc. and affiliated entities across the general ledger, including investments, prepaids, PP&E, leases, accrued expenses, and accounts payable.
  • Support the accrual of clinical vendor and principal investigator expenses.
  • Review daily cash transactions and record cash transactions accurately and timely in Oracle Fusion.
  • Perform monthly account analyses and FloQast reconciliations and support the entry of FX rates in Oracle.
  • Review and process credit card expense reports and receipts for policy compliance and ensure appropriate accounting for expense report transactions.
  • Review, approve and pay out weekly employee expense reports through Concur system
  • Serve as backup to the Accounts Payable team in AP batch processes, as necessary.
  • Maintain SOX internal controls documentation over responsible areas.
  • Assist with preparing schedules for SEC reporting and as support for external audits and reviews, including the PP&E roll forward.
  • Maintain effective relationships with other departments to ensure effective and efficient cross-functional collaboration
Desired Qualifications
  • Prior relevant experience and solid knowledge of US GAAP
  • Bachelor’s degree in accounting preferred
  • Previous experience with accounting systems; knowledge of Oracle Fusion is a plus
  • Prior experience with SAP Concur or FloQast is a plus

Replimune develops cancer therapies that use engineered viruses (oncolytic immunotherapies) to attack tumors. These treatments selectively infect cancer cells, causing their destruction, and at the same time stimulate the immune system to recognize and fight tumors. By combining multiple methods of action, Replimune aims to boost the effectiveness of existing immune checkpoint inhibitors and create a stronger anti-tumor response. The company focuses on research, development, and clinical testing, and plans to earn revenue through partnerships, licensing, and eventual sales of approved therapies. Its goal is to deliver workable cancer treatments by validating safety and efficacy in clinical trials and bringing these therapies to patients with various cancers.

Company Size

201-500

Company Stage

IPO

Headquarters

Woburn, Massachusetts

Founded

2015

Get referred to Replimune Group

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • RP2-202 randomized Phase 2/3 trial enrolls ~280 patients in checkpoint-naïve uveal melanoma, addressing critical unmet need.
  • RP2 FIH data showed 33.3% pooled ORR in uveal melanoma with durable responses up to 27.3+ months.
  • RP2 reprograms cold tumors to immune-inflamed, expanding TCR clones and confirming systemic immune engagement mechanism.

What critics are saying

  • Second FDA rejection of RP1 due to inadequate trial design caused 224 job cuts and $269M cash runway risk.
  • Class action lawsuits for securities fraud tied to FDA rejections expose legal liability and reputational damage.
  • RP2 Phase 2/3 approval may be delayed or denied if FDA applies same 'not well-controlled' scrutiny as RP1.

What makes Replimune Group unique

  • RP2 adds anti-CTLA-4 molecule and GM-CSF to HSV-1, enhancing tumor killing and systemic immune response.
  • RPx platform enables dual local tumor killing and systemic T-cell activation, overcoming checkpoint inhibitor resistance.
  • Focus on rare uveal melanoma and HCC with unmet needs, positioning RP2 as a potential new standard of care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Performance Bonus

Company Equity

Growth & Insights

Headcount

6 month growth

11%

1 year growth

14%

2 year growth

14%